



## **ROCHE AND GENMAB REACH SECOND MILESTONE IN COLLABORATION**

technologies, making it an industry leader. Through its alliance strategy, Roche creates value with its partners by transforming these business transactions into productive relationships that allow for mutual growth and expansion. As evidence of this development plan, in just eight months, Roche and its partners have renewed or broadened eight ongoing alliances. Roche is committed to an alliance strategy that enables its partners to achieve their vision while maintaining their cultural identity and entrepreneurial spirit.

### **Conference call**

Genmab's Management will hold a conference call to discuss the news today, 27 October, 2003 at:

4:00 pm CET

3:00 pm BST

10:00 am US Eastern Time

The dial in numbers are as follows:

**+1-800-915-4836** (in the US) and ask for the Genmab conference call

**+1-973-317-5319** (outside the US) and ask for the Genmab conference call

The conference call will be held in English.

### **About Genmab A/S**

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb™ platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab is headquartered in Copenhagen, Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit [www.genmab.com](http://www.genmab.com).

### **About Roche**

Headquartered in Basel, Switzerland, F. Hoffmann-La Roche (Roche) is one of the world's leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer, and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, Roche contributes on a broad range of fronts to improving people's health and quality of life. Roche employs roughly 62,000 people in 150 countries. Roche

## ROCHE AND GENMAB REACH SECOND MILESTONE IN COLLABORATION

has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai. For more information, access [www.roche.com](http://www.roche.com).

*Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements, e.g. unforeseen exchange rate and interest rate fluctuations, delayed or unsuccessful development projects.*

*Statements that are not historical facts, including statements preceded by, followed by, or that include the words “believes”; “anticipates”; “plans”; “expects”; “estimates”; or similar statements are forward-looking statements. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.*

###